United Therapeutics Payments To Acquire Equity Securities Without Readily Determinable Fair Value remained flat by 0.0% to $25.00M in Q1 2026 compared to the prior quarter.
Increased activity signals a strategic push into new innovation areas or partnerships, while low activity suggests a focus on core internal operations.
These are cash payments for equity investments in other entities where the fair value is not readily determinable, such...
Common among large biotech firms that act as corporate venture capitalists to supplement their internal R&D pipelines.
investing_payments_to_acquire_equity_securities_without__74f804| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $375.00K | $375.00K | $375.00K | $375.00K | $0.00 | $0.00 | $0.00 | $0.00 | $7.63M | $7.63M | $7.63M | $7.63M | $0.00 | $0.00 | $30.00M | $25.00M | $25.00M |
| QoQ Change | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | -16.7% | +0.0% |
| YoY Change | — | — | — | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -100.0% | -100.0% | +293.4% | +227.9% | — |